Envestnet Asset Management Inc Nektar Therapeutics Transaction History

Envestnet Asset Management Inc

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$0.51 - $1.05 $23,644 - $48,679	-46,361 Reduced 73.11%	17,050 $10,000
Q2 2023 Aug 04, 2023	BUY	$0.53 - $1.03 $33,607 - $65,313	63,411 New	63,411 $36,000
Q1 2022 May 04, 2022	SELL	$4.16 - $13.72 $59,525 - $196,319	-14,309 Closed	0 $0
Q4 2021 Feb 04, 2022	SELL	$10.83 - $18.41 $2,804 - $4,768	-259 Reduced 1.78%	14,309 $193,000
Q3 2021 Oct 07, 2021	BUY	$13.07 - $18.84 $13,122 - $18,915	1,004 Added 7.4%	14,568 $262,000

Q2 2021 Aug 04, 2021	SELL	$16.52 - $20.4 $51,971 - $64,178	-3,146 Reduced 18.83%	13,564 $233,000
Q1 2021 May 04, 2021	BUY	$16.56 - $25.46 $77,832 - $119,662	4,700 Added 39.13%	16,710 $334,000
Q4 2020 Feb 02, 2021	BUY	$15.77 - $19.03 $189,397 - $228,550	12,010 New	12,010 $204,000
Q3 2019 Oct 17, 2019	SELL	$16.91 - $36.27 $116,137 - $249,102	-6,868 Closed	0 $0
Q2 2019 Aug 02, 2019	SELL	$31.0 - $36.3 $14,353 - $16,806	-463 Reduced 6.32%	6,868 $244,000
Q1 2019 May 10, 2019	SELL	$31.58 - $46.35 $12,789 - $18,771	-405 Reduced 5.24%	7,331 $246,000
Q4 2018 Feb 13, 2019	SELL	$30.43 - $56.65 $1.75 Million - $3.25 Million	-57,400 Reduced 88.12%	7,736 $254,000
Q3 2018 Nov 14, 2018	BUY	$46.46 - $68.49 $2.98 Million - $4.39 Million	64,149 Added 6499.39%	65,136 $3.97 Million
Q2 2018 Aug 10, 2018	SELL	$46.25 - $104.45 $4,116 - $9,296	-89 Reduced 8.27%	987 $47,000
Q1 2018 May 09, 2018	BUY	$57.4 - $108.44 $12,513 - $23,639	218 Added 25.41%	1,076 $109,000
Q4 2017 Feb 20, 2018	BUY	$23.02 - $60.5 $19,751 - $51,909	858	858 $51,000

128

111M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $219M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Envestnet Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Envestnet Asset Management Inc with notifications on news.